everolimus
NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment
January 13, 2017Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus
In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …
EU approval for Eisai kidney cancer treatment
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Eisai submits new cancer combo to EMA for approval
January 12, 2016Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib
Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
Mixed bag for Novartis and Astellas in breast cancer
December 15, 2014Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus
Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …
Another approval for Novartis’ everolimus
February 18, 2013Sales and Marketing Certican, Novartis, Zortress, everolimus
Novartis has gained US approval for its drug Zortress (everolimus) to prevent liver transplant rejection.Zotress is already used to prevent …
Everolimus approved to treat rare tumour disease
September 8, 2011Sales and Marketing Novartis, SEGA, Votubia, everolimus
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
Novartis’ Votubia reduces benign brain tumours in SEGA patients
July 11, 2011Research and Development Novartis, SEGA, Votubia, everolimus
Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …
Regulators back Novartis’ Votubia
June 28, 2011Sales and Marketing Novartis, Votubia, everolimus
Novartis’ drug Votubia has been recommended by regulators to treat a disease for which the only current option in Europe …
Novartis fails to sway NICE with Afinitor deal
November 26, 2010Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus
Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
